Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
74.13
-3.10 (-4.01%)
Feb 27, 2026, 4:00 PM EST - Market closed
Inhibrx Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 1.4 | 0.2 | 1.8 | 1.32 | 7.23 |
| Revenue Growth (YoY) | -19.26% | -88.89% | 36.88% | -81.81% | - |
| Cost of Revenue | 146.95 | 203.74 | 191.64 | 101.6 | 71.44 |
| Gross Profit | -145.55 | -203.54 | -189.84 | -100.29 | -64.21 |
| Selling, General & Admin | 49.58 | 59.84 | 29.35 | 15.04 | 12.36 |
| Operating Expenses | 49.58 | 59.84 | 29.35 | 15.04 | 12.36 |
| Operating Income | -195.13 | -263.39 | -219.19 | -115.32 | -76.56 |
| Interest Expense | -9.01 | -13.49 | -31.84 | - | - |
| Interest & Investment Income | 8.24 | 10.94 | 11.92 | - | - |
| Earnings From Equity Investments | - | - | -1.63 | - | - |
| Other Non Operating Income (Expenses) | -0.28 | 0.08 | -0.58 | 0 | -5.2 |
| EBT Excluding Unusual Items | -196.18 | -265.86 | -241.32 | -115.32 | -81.77 |
| Merger & Restructuring Charges | 41.1 | -68.06 | -0.04 | - | - |
| Other Unusual Items | - | 2,021 | - | - | - |
| Pretax Income | -155.08 | 1,688 | -241.36 | -115.32 | -81.77 |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | -155.09 | 1,688 | -241.36 | -115.33 | -81.77 |
| Net Income to Common | -155.09 | 1,688 | -241.36 | -115.33 | -81.77 |
| Shares Outstanding (Basic) | 15 | 15 | 12 | 40 | 38 |
| Shares Outstanding (Diluted) | 15 | 15 | 12 | 40 | 38 |
| Shares Change (YoY) | 6.72% | 27.17% | -70.62% | 5.52% | - |
| EPS (Basic) | -10.02 | 114.01 | -20.48 | -2.88 | -2.15 |
| EPS (Diluted) | -10.03 | 112.62 | -20.48 | -2.88 | -2.15 |
| Free Cash Flow | -143.44 | -197.01 | -197.9 | -91.5 | - |
| Free Cash Flow Per Share | -9.27 | -13.15 | -16.80 | -2.28 | - |
| Operating Margin | -13937.86% | -131693.50% | -12176.94% | -8769.81% | -1058.83% |
| Profit Margin | -11077.57% | 843786.00% | -13408.94% | -8769.96% | -1130.80% |
| Free Cash Flow Margin | -10245.64% | -98503.00% | -10994.56% | -6957.95% | - |
| EBITDA | -192.52 | -261.1 | -217.99 | -114.1 | - |
| D&A For EBITDA | 2.61 | 2.29 | 1.19 | 1.23 | - |
| EBIT | -195.13 | -263.39 | -219.19 | -115.32 | -76.56 |
| Revenue as Reported | 1.4 | 0.2 | 1.8 | 1.32 | 7.23 |
Source: S&P Capital IQ. Standard template.
Financial Sources.